IL95849A - An anticoagulant preparation containing acetylsalicylic acid and a history of carbacicline - Google Patents

An anticoagulant preparation containing acetylsalicylic acid and a history of carbacicline

Info

Publication number: IL95849A
Authority: IL; Israel
Prior art keywords: cicaprost; composition according; carbacyclin; asa; acetylsalicylic acid
Prior art date: 1989-09-29

Application number

IL9584990A

Other languages

English (en)

Hebrew (he)

Other versions

IL95849A0 (en

Original Assignee

Schering Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-09-29

Filing date

1990-09-28

Publication date

1995-03-30

1990-09-28 Application filed by Schering Ag filed Critical Schering Ag

1991-06-30 Publication of IL95849A0 publication Critical patent/IL95849A0/xx

1995-03-30 Publication of IL95849A publication Critical patent/IL95849A/en

Links

XZFRIPGNUQRGPI-WLPVIMDJSA-N Carbacyclin Chemical class C1\C(=C\CCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 XZFRIPGNUQRGPI-WLPVIMDJSA-N 0.000 title claims abstract description 21
239000008194 pharmaceutical composition Substances 0.000 title claims description 3
230000002785 anti-thrombosis Effects 0.000 title description 7
239000003146 anticoagulant agent Substances 0.000 title description 6
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims abstract description 44
229960001138 acetylsalicylic acid Drugs 0.000 claims abstract description 18
208000007536 Thrombosis Diseases 0.000 claims abstract description 15
238000011282 treatment Methods 0.000 claims abstract description 5
ARUGKOZUKWAXDS-SEWALLKFSA-N cicaprost Chemical group C1\C(=C/COCC(O)=O)C[C@@H]2[C@@H](C#C[C@@H](O)[C@@H](C)CC#CCC)[C@H](O)C[C@@H]21 ARUGKOZUKWAXDS-SEWALLKFSA-N 0.000 claims description 39
229950000634 cicaprost Drugs 0.000 claims description 39
239000000203 mixture Substances 0.000 claims description 18
MAUUNYHAXGTMMQ-AMXXQSRZSA-N 4-[(2e)-2-[(3as,4s,5r,6as)-5-hydroxy-4-[(3s,4s)-3-hydroxy-4-methylnona-1,6-diynyl]-3,3a,4,5,6,6a-hexahydro-1h-pentalen-2-ylidene]ethoxy]butanoic acid Chemical compound C1\C(=C/COCCCC(O)=O)C[C@@H]2[C@@H](C#C[C@@H](O)[C@@H](C)CC#CCC)[C@H](O)C[C@@H]21 MAUUNYHAXGTMMQ-AMXXQSRZSA-N 0.000 claims description 12
229950006293 eptaloprost Drugs 0.000 claims description 12
229920000858 Cyclodextrin Polymers 0.000 claims description 10
230000005764 inhibitory process Effects 0.000 claims description 10
150000003839 salts Chemical class 0.000 claims description 6
239000001116 FEMA 4028 Substances 0.000 claims description 5
WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical group OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 5
235000011175 beta-cyclodextrine Nutrition 0.000 claims description 5
229960004853 betadex Drugs 0.000 claims description 5
125000005273 2-acetoxybenzoic acid group Chemical group 0.000 claims 1
238000002360 preparation method Methods 0.000 abstract description 4
210000001772 blood platelet Anatomy 0.000 description 19
102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 10
108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 10
239000000126 substance Substances 0.000 description 10
XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 description 9
XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 9
102000012335 Plasminogen Activator Inhibitor 1 Human genes 0.000 description 9
108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 9
108010035532 Collagen Proteins 0.000 description 8
102000008186 Collagen Human genes 0.000 description 8
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 8
229920001436 collagen Polymers 0.000 description 8
239000000243 solution Substances 0.000 description 8
238000004220 aggregation Methods 0.000 description 7
230000002776 aggregation Effects 0.000 description 7
230000015572 biosynthetic process Effects 0.000 description 7
150000001875 compounds Chemical class 0.000 description 7
206010043554 thrombocytopenia Diseases 0.000 description 7
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
239000003112 inhibitor Substances 0.000 description 6
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
230000002792 vascular Effects 0.000 description 6
241000700199 Cavia porcellus Species 0.000 description 5
238000012360 testing method Methods 0.000 description 5
230000002885 thrombogenetic effect Effects 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 4
102000001554 Hemoglobins Human genes 0.000 description 4
108010054147 Hemoglobins Proteins 0.000 description 4
230000009471 action Effects 0.000 description 4
210000002565 arteriole Anatomy 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
230000000694 effects Effects 0.000 description 4
235000002639 sodium chloride Nutrition 0.000 description 4
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
230000004913 activation Effects 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
229960004676 antithrombotic agent Drugs 0.000 description 3
210000001715 carotid artery Anatomy 0.000 description 3
239000012230 colorless oil Substances 0.000 description 3
238000001704 evaporation Methods 0.000 description 3
230000008020 evaporation Effects 0.000 description 3
-1 fatty acid monoglycerides Chemical class 0.000 description 3
208000014674 injury Diseases 0.000 description 3
239000000741 silica gel Substances 0.000 description 3
229910002027 silica gel Inorganic materials 0.000 description 3
230000001225 therapeutic effect Effects 0.000 description 3
230000001732 thrombotic effect Effects 0.000 description 3
230000008733 trauma Effects 0.000 description 3
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
241000700198 Cavia Species 0.000 description 2
238000002965 ELISA Methods 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
108010003541 Platelet Activating Factor Proteins 0.000 description 2
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
238000000692 Student's t-test Methods 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
229910052786 argon Inorganic materials 0.000 description 2
210000001367 artery Anatomy 0.000 description 2
230000003143 atherosclerotic effect Effects 0.000 description 2
239000012752 auxiliary agent Substances 0.000 description 2
239000012267 brine Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
229960001123 epoprostenol Drugs 0.000 description 2
KAQKFAOMNZTLHT-VVUHWYTRSA-N epoprostenol Chemical compound O1C(=CCCCC(O)=O)C[C@@H]2[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]21 KAQKFAOMNZTLHT-VVUHWYTRSA-N 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
SHFJWMWCIHQNCP-UHFFFAOYSA-M hydron;tetrabutylazanium;sulfate Chemical compound OS([O-])(=O)=O.CCCC[N+](CCCC)(CCCC)CCCC SHFJWMWCIHQNCP-UHFFFAOYSA-M 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
239000008101 lactose Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
238000005259 measurement Methods 0.000 description 2
239000012074 organic phase Substances 0.000 description 2
230000010118 platelet activation Effects 0.000 description 2
239000000106 platelet aggregation inhibitor Substances 0.000 description 2
210000004623 platelet-rich plasma Anatomy 0.000 description 2
238000003127 radioimmunoassay Methods 0.000 description 2
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
238000012353 t test Methods 0.000 description 2
239000000454 talc Substances 0.000 description 2
229910052623 talc Inorganic materials 0.000 description 2
230000009424 thromboembolic effect Effects 0.000 description 2
229960000187 tissue plasminogen activator Drugs 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
UCTWMZQNUQWSLP-UHFFFAOYSA-N Adrenaline Natural products CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 1
229920000856 Amylose Polymers 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
229940122204 Cyclooxygenase inhibitor Drugs 0.000 description 1
101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 description 1
101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 description 1
LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
239000001828 Gelatine Substances 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
ZNSPHKJFQDEABI-NZQKXSOJSA-N Nc1nc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)cc(n1)N1CCC2(CN[C@@H](C2)C(O)=O)CC1 Chemical compound Nc1nc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)cc(n1)N1CCC2(CN[C@@H](C2)C(O)=O)CC1 ZNSPHKJFQDEABI-NZQKXSOJSA-N 0.000 description 1
108010001014 Plasminogen Activators Proteins 0.000 description 1
102000001938 Plasminogen Activators Human genes 0.000 description 1
206010050661 Platelet aggregation inhibition Diseases 0.000 description 1
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
229910000831 Steel Inorganic materials 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
239000012190 activator Substances 0.000 description 1
229940102884 adrenalin Drugs 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229910001854 alkali hydroxide Inorganic materials 0.000 description 1
150000008044 alkali metal hydroxides Chemical class 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
229940127218 antiplatelet drug Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
230000036523 atherogenesis Effects 0.000 description 1
239000002585 base Substances 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
230000017531 blood circulation Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
239000000920 calcium hydroxide Substances 0.000 description 1
229910001861 calcium hydroxide Inorganic materials 0.000 description 1
239000002775 capsule Substances 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
230000008859 change Effects 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000015271 coagulation Effects 0.000 description 1
238000005345 coagulation Methods 0.000 description 1
229960005188 collagen Drugs 0.000 description 1
238000004040 coloring Methods 0.000 description 1
239000013066 combination product Substances 0.000 description 1
229940127555 combination product Drugs 0.000 description 1
229940125876 compound 15a Drugs 0.000 description 1
238000001816 cooling Methods 0.000 description 1
230000002079 cooperative effect Effects 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
230000000875 corresponding effect Effects 0.000 description 1
239000013078 crystal Substances 0.000 description 1
229940097362 cyclodextrins Drugs 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000010102 embolization Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
210000003989 endothelium vascular Anatomy 0.000 description 1
IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
230000020764 fibrinolysis Effects 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
230000002178 gastroprotective effect Effects 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
150000004679 hydroxides Chemical class 0.000 description 1
229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
238000000034 method Methods 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
239000012188 paraffin wax Substances 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
239000002304 perfume Substances 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000000825 pharmaceutical preparation Substances 0.000 description 1
229940127126 plasminogen activator Drugs 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
239000002599 prostaglandin synthase inhibitor Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
238000007127 saponification reaction Methods 0.000 description 1
HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
238000005584 silyl ether cleavage reaction Methods 0.000 description 1
210000000329 smooth muscle myocyte Anatomy 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
229910052938 sodium sulfate Inorganic materials 0.000 description 1
235000011152 sodium sulphate Nutrition 0.000 description 1
239000007787 solid Substances 0.000 description 1
208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000010959 steel Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
238000005728 strengthening Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
230000002195 synergetic effect Effects 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000003826 tablet Substances 0.000 description 1
235000012222 talc Nutrition 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
238000004448 titration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
229960005356 urokinase Drugs 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Diabetes (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Materials For Medical Uses (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Plant Substances (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

IL9584990A 1989-09-29 1990-09-28 An anticoagulant preparation containing acetylsalicylic acid and a history of carbacicline IL95849A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE3933027A DE3933027A1 (de)	1989-09-29	1989-09-29	Kombinationspraeparat mit antithrombotischer wirkung

Publications (2)

Publication Number	Publication Date
IL95849A0 IL95849A0 (en)	1991-06-30
IL95849A true IL95849A (en)	1995-03-30

Family

ID=6390758

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL9584990A IL95849A (en)	1989-09-29	1990-09-28	An anticoagulant preparation containing acetylsalicylic acid and a history of carbacicline

Country Status (19)

Country	Link
US (1)	US5093325A (cs)
EP (1)	EP0420368B1 (cs)
JP (1)	JP3040463B2 (cs)
AT (1)	ATE92325T1 (cs)
CA (1)	CA2069296C (cs)
CS (1)	CS277650B6 (cs)
DD (1)	DD299153A5 (cs)
DE (2)	DE3933027A1 (cs)
DK (1)	DK0420368T3 (cs)
ES (1)	ES2058771T3 (cs)
HU (1)	HUT60140A (cs)
IE (1)	IE903503A1 (cs)
IL (1)	IL95849A (cs)
NO (1)	NO921223L (cs)
NZ (1)	NZ235521A (cs)
PT (1)	PT95456B (cs)
RU (1)	RU2097039C1 (cs)
WO (1)	WO1991004740A1 (cs)
ZA (1)	ZA907808B (cs)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040180865A1 (en) *	1993-06-04	2004-09-16	Jeffry W. Kreamer	Aspirin and vitamin and/or trace element compositions for the amelioration and treatment of vascular disease
US5830837A (en) *	1994-11-22	1998-11-03	Novo Nordisk A/S	Amylase variants
US5709541A (en) *	1995-06-26	1998-01-20	Selas Corporation Of America	Method and apparatus for reducing NOx emissions in a gas burner
DE19530884C2 (de) *	1995-08-11	1997-07-31	Schering Ag	Verwendung von Prostan-Derivaten sowie deren Kombination mit Antibiotika zur Behandlung von bakteriellen Meningitis
US6010911A (en) *	1997-04-30	2000-01-04	Medtronic, Inc.	Apparatus for performing a heparin-independent high sensitivity platelet function evaluation technique
MY129350A (en) *	2001-04-25	2007-03-30	Bristol Myers Squibb Co	Aripiprazole oral solution
WO2004071508A1 (en) *	2003-02-14	2004-08-26	Medical Research Council	Ip receptor antagonists for the treatment of pathological uterine conditions
JP2007538257A (ja) *	2004-05-17	2007-12-27	メドトロニック・インコーポレーテッド	ポイント・オブ・ヘパリン測定システム
DK2026651T3 (da) *	2006-03-08	2013-07-08	Cortria Corp	Kombinationsterapi med ikke-selektive COX-inhibitorer til forebyggelse af COX-relaterede maveskader
RU2440370C2 (ru) *	2010-04-05	2012-01-20	Государственное Образовательное Учреждение Высшего Профессионального Образования Амурская Государственная Медицинская Академия Росздрава	Способ усиления антиагрегантной активности
US20130040898A1 (en) *	2010-04-29	2013-02-14	Pär Johansson	Methods of treatment of patients at increased risk of development of ischemic events and compounds hereof
US9345678B2 (en) *	2013-03-13	2016-05-24	Allergan, Inc.	Prostanoid receptor agonist compounds and methods of use for same

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3524051A1 (de) *	1985-07-05	1987-01-15	Hoechst Ag	Kombinationspraeparate aus hemmstoffen der thrombozytenaggregation und deren verwendung

1989
- 1989-09-29 DE DE3933027A patent/DE3933027A1/de not_active Withdrawn
1990
- 1990-09-28 CS CS904726A patent/CS277650B6/cs not_active IP Right Cessation
- 1990-09-28 PT PT95456A patent/PT95456B/pt not_active IP Right Cessation
- 1990-09-28 IL IL9584990A patent/IL95849A/en not_active IP Right Cessation
- 1990-09-28 ZA ZA907808A patent/ZA907808B/xx unknown
- 1990-10-01 DD DD90344337A patent/DD299153A5/de not_active IP Right Cessation
- 1990-10-01 IE IE350390A patent/IE903503A1/en not_active IP Right Cessation
- 1990-10-01 DK DK90250248.3T patent/DK0420368T3/da active
- 1990-10-01 JP JP2513226A patent/JP3040463B2/ja not_active Expired - Fee Related
- 1990-10-01 US US07/591,108 patent/US5093325A/en not_active Expired - Fee Related
- 1990-10-01 RU SU5011616/14A patent/RU2097039C1/ru not_active IP Right Cessation
- 1990-10-01 ES ES90250248T patent/ES2058771T3/es not_active Expired - Lifetime
- 1990-10-01 CA CA002069296A patent/CA2069296C/en not_active Expired - Fee Related
- 1990-10-01 AT AT90250248T patent/ATE92325T1/de not_active IP Right Cessation
- 1990-10-01 DE DE9090250248T patent/DE59002185D1/de not_active Expired - Lifetime
- 1990-10-01 WO PCT/DE1990/000750 patent/WO1991004740A1/de not_active Ceased
- 1990-10-01 HU HU9201045A patent/HUT60140A/hu not_active IP Right Cessation
- 1990-10-01 EP EP90250248A patent/EP0420368B1/de not_active Expired - Lifetime
- 1990-10-01 NZ NZ235521A patent/NZ235521A/xx unknown
1992
- 1992-03-27 NO NO92921223A patent/NO921223L/no unknown

Also Published As

Publication number	Publication date
RU2097039C1 (ru)	1997-11-27
US5093325A (en)	1992-03-03
EP0420368A1 (de)	1991-04-03
DE59002185D1 (de)	1993-09-09
WO1991004740A1 (de)	1991-04-18
DE3933027A1 (de)	1991-04-11
JPH05500805A (ja)	1993-02-18
NO921223D0 (no)	1992-03-27
EP0420368B1 (de)	1993-08-04
NZ235521A (en)	1993-03-26
ATE92325T1 (de)	1993-08-15
HU9201045D0 (en)	1992-06-29
CA2069296A1 (en)	1991-03-30
DK0420368T3 (da)	1993-11-15
DD299153A5 (de)	1992-04-02
HUT60140A (en)	1992-08-28
IE903503A1 (en)	1991-04-10
PT95456B (pt)	1997-07-31
AU6419090A (en)	1991-04-28
NO921223L (no)	1992-03-27
CA2069296C (en)	2002-04-23
ZA907808B (en)	1992-01-29
ES2058771T3 (es)	1994-11-01
IL95849A0 (en)	1991-06-30
CS277650B6 (en)	1993-03-17
JP3040463B2 (ja)	2000-05-15
AU640692B2 (en)	1993-09-02
PT95456A (pt)	1991-08-14
CS472690A3 (en)	1992-08-12

Legal Events

Date	Code	Title	Description
1996-11-14	KB	Patent renewed
2005-07-25	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
Hursting et al.	1997	Novastan®(brand of argatroban): a small-molecule, direct thrombin inhibitor
US5093325A (en)	1992-03-03	Combination preparation having antithrombotic action
CN1116042C (zh)	2003-07-30	含有氯吡格雷和一种抗血栓形成药活性成分的组合物
Chong et al.	1981	Heparin‐induced thrombocytopenia: effect of heparin platelet antibody on platelets
US4451454A (en)	1984-05-29	Prophylaxis and treatment of thromboembolic disorders in man and in warm-blooded animals with bicarbonate salts of alkali metals
JPH04504710A (ja)	1992-08-20	抗血栓組成物
Küster et al.	1986	Platelet aggregation and thromboxane release induced by arachidonic acid, collagen, ADP and platelet-activating factor following low dose acetylsalicylic acid in man
Louie et al.	1988	Diadenosine 5′, 5‴-p1, p4-tetraphosphate, a potential antithrombotic agent
Tohgi et al.	1988	Individual variation in platelet aggregability and serum thromboxane B2 concentrations after low-dose aspirin.
Silver et al.	1974	Blood platelets and the inflammatory process
Hornstra et al.	1979	Clot-promoting effect of platelet-vessel wall interaction: influence of dietary fats and relation to arterial thrombus formation in rats
JPS6257605B2 (cs)	1987-12-02
US4097602A (en)	1978-06-27	Method of inhibiting blood platelet aggregation
WO1999049865A1 (en)	1999-10-07	Use of platelet activating factor (paf) inhibitors to inhibit il-5 induced eosinophil activation or degranulation
AU660449B2 (en)	1995-06-29	Prostacycline and carbacycline derivatives as agents for treating feverish complaints
Hall et al.	1982	The reduction of platelet thrombi on damaged vessel wall by a thromboxane synthetase inhibitor in rabbits
Ito et al.	1990	Role of activated platelets in endotoxin-induced DIC in rats
Deen Jr et al.	1982	The effect of combined aspirin and dipyridamole therapy on thrombus formation in an arterial thrombogenic lesion in the dog.
US4705792A (en)	1987-11-10	4-amino-2-(imidazolidin-2-on-1-yl)-5-(3-trifluoromethyl-phenyllaminocarbonyl)pyrimidines for antithrombotic prophylaxis and treatment
JPH10501554A (ja)	1998-02-10	新規な止血剤組成物
Nagatsuka et al.	1985	A new approach to antithrombotic therapy--evaluation of combined therapy of thromboxane synthetase inhibitor and very low dose of aspirin.
IE59338B1 (en)	1994-02-09	Prostacyclins, their analogues or prostaglandins and thromboxane antagonists for the treatment of thrombotic and thrombo-embolic syndromes
AU2002363023B2 (en)	2007-10-25	A combination product comprising melagatran and dexamethasone
BOLTON	1985	Disseminated intravascular coagulation
JP3169343B2 (ja)	2001-05-21	アスピリンおよび抗−Ｘａオリゴ糖の組合せを含有する組成物ならびにアスピリンと任意的に組み合わせた抗−Ｘａオリゴ糖の使用